TScan Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of theSecurities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties.All statements, other than statements of historical facts, contained in this Quarterly Report are forward-lookingstatements. In some cases, you can identify forward-looking statements by words such as “may,” “can,” “will,” “should,”“would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “seek,” “contemplate,” “believe,”“estimate,” “predict,” “potential,” “possible” or “continue” or the negative of these terms or other similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements containthese identifying words. Forward-looking statements contained in this Quarterly Report include, but are not limitedto, statements about: •the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our T cellreceptor (TCR)-engineered T cell, or TCR-T, therapy product candidates;•our expectations regarding our preclinical studies being predictive of clinical trial results;•the timing of the initiation, progress and expected results of our preclinical studies, clinical trials and ourresearch and development programs;•the timing of and our ability to submit applications for, and obtain and, if approved, maintain regulatoryapprovals for our TCR-T therapy product candidates;•ourexpectations regarding clinical trial results being predictive of continued development andcommercial success of our product candidates;•our plans relating to developing and commercializing our TCR-T therapy product candidates, ifapproved, including sales strategy;•estimates of the size of the addressable market for our TCR-T therapy product candidates;•our manufacturing capabilities and the scalable nature of our manufacturing process;•our estimates regarding expenses, future milestone payments and revenue, capital requirements andneeds for additional financing;•our expectations regarding competition;•our anticipated growth strategies;•our ability to attract or retain key personnel;•our ability to establish and maintain development partnerships and collaborations;•our expectations regarding federal, state and foreign regulatory requirements;•regulatory developments in the U.S. and foreign countries;•our ability to obtain and maintain intellectual property protection for our proprietary platform technologyand our product candidates;•the anticipated trends and challenges in our business and the market in which we operate;•the sufficiency of our existing capital resources to fund our future operating expenses and capitalexpenditure requirements;•the effects of rising inflation rates and the impact on operating costs, liquidity and access to credit on anyof the foregoing or other aspects of our business operations;•the effects of global economic uncertainty and financial market volatility caused by political instability,newor increased international tariffs and retaliatory tariffs,changes in U.S.policy,changes ingovernmental agencies, changes in international trade relationships and conflicts, such as the ongoingconflict between Russia and Ukraine, on any of the foregoing or other aspects of our business oroperation